Homology Medicines Inc. Stock News

Penny stocks hold a distinctive charm for many investors. Amidst fluctuating market trends and the occasional downturn, there's often a group of these low-cost stocks surging in value.

There's something special about penny stocks. Even when the stock market is down, like it is today, you're likely to find at least a handful exploding higher.

Homology Medicines (FIXX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.20 per share a year ago.

Homology Medicines (FIXX) delivered earnings and revenue surprises of -17.65% and 23.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts say these are penny stocks to buy but do you agree? The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 1,050% appeared first on Penny Stocks to Buy, Picks, News and Informati

Homology Medicines (FIXX) delivered earnings and revenue surprises of 10.53% and 23.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BEDFORD, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following conferences:

Homology Medicines (FIXX) delivered earnings and revenue surprises of 20% and 38.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Homology Medicines (FIXX) delivered earnings and revenue surprises of -1.72% and 19.80%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

After losing some value lately, a hammer chart pattern has been formed for Homology Medicines (FIXX), indicating that the stock has found support. This, combined with an upward trend in earnings estim

Homology Medicines (FIXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Homology Medicines (FIXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BEDFORD, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation at the following virtual investor conferences:

Gainers Mullen Automotive, Inc. (NASDAQ: MULN ) jumped 74.4% to $1.20 after the company reported progress on solid-state polymer battery pack development. Renewable Energy Group, Inc. (NASDAQ: REGI ) shares jumped 38.7% to $60.75 after Chevron Corp (NYSE: CVX ) announced an agreement to acquire the company. IntriCon Corporation (NASDAQ: IIN ) gained 37.3% to $23.91 after the company agreed to be acquired by an affiliate of Altaris Capital Partners for $241 million. IntriCon also posted Q4 EPS of $0.23. NeuroSense Therapeutics Ltd. (NASDAQ: NRSN ) climbed 30.5% to $2.01 after gaining around 8% on Friday. First Horizon Corporation (NYSE: FHN ) shares climbed 30.4% to $23.80 after TD announced acquisition of the company for $25 per share in cash. Imperial Petroleum Inc. (NASDAQ: IMPP ) shares rose 26% to $2.6450 after jumping around 34% on Friday. Everbridge, Inc. (NASDAQ: EVBG ) gained 23% to $37.67. Lifeway Foods, Inc. (NASDAQ: LWAY ) surged 20% to $6.60. Azure Power Global Limited (NYSE: AZRE ) gained 19.9% to $18.76.

Homology Medicines (FIXX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in